Navigation Links
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Date:12/12/2009

SAN ANTONIO, TXA new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

The findings will be presented at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12 (Abstract 710, Henry B. Gonzalez Convention Center, Exhibit Hall B, 7-9 a.m. CT).

Ian Krop, MD, PhD, principal investigator of the study, will report that the hybrid agent, called T-DM1, shrank tumors by 30 percent or more in 40 percent of women with confirmed HER2-positive cancers. Another 13 percent had stable disease for at least six months, for a total clinical benefit rate of approximately 53 percent. The median time before the disease progressed was 7.3 months, including both responders and non-responders. Patients received T-DM1 as long as it was effective and well-tolerated. A total of 110 women were enrolled in the study.

T-DM1 is comprised of the cell-killing drug DM1 and is chemically linked to the monoclonal antibody trastuzumab, which selectively binds to the HER2 growth signal receptor, which is highly overexpressed in HER2-positive breast tumors. Approximately 20 percent of breast cancers are HER2-postive.

Trastuzumab, developed by Genentech and sold under the name Herceptin, has markedly improved the treatment of HER2-positive cancer, but resistance to trastuzumab is a significant problem.

"The antibody binds to the HER2 protein on tumor cells and delivers the drug (DM1) selectively to them but not to normal cells," Krop explained. "This allows us to deliver high doses of the chemotherapy directly to tumor cells. And at the same time, the antibody continues to block the HER2 growth signals."

Krop said that one of the unique features of the study is that it is the first to address a population of women with metastatic HER2-positive breast cancer whose disease had progressed despite treatment with all of the FDA-approved drugs for this disease (trastuzumab, lapatinib and several chemotherapy agents).

On average, the women had metastatic breast cancer for three years and previously received seven different drugs for their cancer.

Although patients experienced side effects that included nausea, fatigue and lowered platelet counts, these effects were typically mild and the drug in general was well-tolerated, said Krop.

In addition to the current study, T-DM1 is being tested in larger Phase 3 trials comparing its effectiveness with that of other combined therapies.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. New research shows how chronic stress worsens neurodegenerative disease course
3. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
4. Circulating fats kill transplanted pancreas cells, study shows
5. New Heart Pump Shows Promise in Trial
6. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
7. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
10. Avocados may help prevent oral cancer, OSU study shows
11. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... NJ (PRWEB) , ... May 31, 2016 , ... Dr. ... Medicine and Dentistry of New Jersey in the class of 1986, where he graduated ... cosmetic dentistry at his current location in Livingston since 1989. He has been a ...
(Date:5/31/2016)... ... 2016 , ... CURE Media Group , the nation’s ... Cancer and Careers to its Advocacy Spotlight Partnership program ... careers while fighting cancer. , As partners, both organizations will supply timely information ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... within Final Cut Pro X. Choose from abstract transitions to more simple wipes ...
(Date:5/30/2016)... ... ... Another ER facility operated by First Choice Emergency Room opened ... and is open 24 hours daily. , First Choice Emergency Room hosted a ribbon ... Jasper High School band entertained attendees and accepted First Choice Emergency Room’s donation on ...
(Date:5/29/2016)... ... , ... "With 30 unique self-animating web themed intros and complete control over ... said Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume ... Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 , Isansys  Lifecare, a new ... Status Engine wireless patient monitoring platform, as it ships more ... Germany , Scotland and ... generation system, launched earlier this year, is now being used ... , This new technology significantly enhances the user ...
(Date:5/30/2016)... 30, 2016 Transparency Market Research ... Visualization Systems Market - Global Industry Analysis, Size, Share, ... the report, the global advanced (3D/4D) visualization systems market ... is anticipated to expand at a CAGR of 6.4% ... in 2024. Advanced (3D/4D) visualization systems have ...
(Date:5/30/2016)... , May 30, 2016 ... to reach USD 7.3 billion by 2024, according ... Inc. The increasing natality rate, the growing malnutrition ... as cancer and gastro-intestinal tract diseases are expected ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
Breaking Medicine Technology: